Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from the FIT Phase 3 clinical program of fostamatinb in chronic immune thrombocytopenia, or ITP
. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA)
and a Phase 2 clinical trial in IgA nephropathy (IgAN)
. In addition, Rigel has two oncology product candidates in development with partners BerGenBio AS
(Phase 2) and Daiichi Sankyo
Recent NewsMore »
|03/07/17||Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update|
|Conference Call and Webcast Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., March 7, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2016.
In August and October 2016, Rigel reported results from the three FIT Phase 3 clinical studies of fostamatinib in immune thrombocytopenia (ITP), which showed a consistent fostamatinib response rate.
In January 2017, ... |
|02/28/17||Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results|
|SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.
Participants can access the live conference call by dialing 855-892-1489 (domestic) or... |
|02/03/17||Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares|
|SOUTH SAN FRANCISCO, Calif., Feb. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the closing of its previously announced underwritten public offering of 23,000,000 shares of its common stock at a price to the public of $2.00 per share, which includes 3,000,000 additional shares of common stock issued upon the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds to Rigel from this offering are $46,000,000, before deduc... |
Upcoming EventsMore »
There are currently no events scheduled.
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|